Literature DB >> 30686681

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

Bo Da Nam1, Tae Jung Kim2, Keunchil Park3, Myung-Ju Ahn3, Yoon-La Choi4, Myung Jin Chung5, Tae Sung Kim5, Kyung Soo Lee5.   

Abstract

PURPOSE: To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic rebiopsy specimens. PATIENTS AND METHODS: We retrospectively reviewed 367 patients with lung adenocarcinoma who underwent transthoracic core needle biopsy for mutation analysis from September 2011 to October 2016. Of these, 199 patients underwent rebiopsy. Patient characteristics, treatment history, target lesion characteristics, and procedure-related factors were evaluated. The adequacy rate of specimens for mutation analysis was evaluated. Univariable and multivariable analyses were performed to determine the independent predictors of nondiagnostic specimens.
RESULTS: Ninety percent of specimens (179 of 199) were adequate for mutation analysis. The EGFR mutation (exon 18-21) was 65% (117 of 179) and the EGFR T790M mutation 33% (59 of 179) of specimens. In univariable analysis, an internal low-attenuation area in the target lesion (P = .001) and pleural contact (P = .004) on computed tomography were significant risk factors for nondiagnostic specimens. In multivariable analysis, an internal low-attenuation area in the target lesion (odds ratio = 7.333; 95% confidence interval, 1.755-30.633; P = .006) was an independent predictor for acquisition of nondiagnostic specimens.
CONCLUSION: Image-guided transthoracic rebiopsy to obtain specimens for mutation analysis in lung adenocarcinoma provides high diagnostic accuracy, with a low rate of nondiagnostic specimens. The presence of internal low-attenuation area in the target lesion on computed tomography was an independent predictor for acquiring nondiagnostic specimens.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopsy; Epidermal growth factor receptor; Lung adenocarcinoma; X-ray computed tomography

Mesh:

Substances:

Year:  2018        PMID: 30686681     DOI: 10.1016/j.cllc.2018.12.021

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

1.  Computed tomography-guided core needle biopsy for sub-centimeter pulmonary nodules.

Authors:  Hui Hui; Hai-Tao Yin; Tao Wang; Gang Chen
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-06-29

Review 2.  Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine.

Authors:  Miyuki Sone; Shunsuke Sugawara; Yasushi Yatabe
Journal:  Curr Oncol Rep       Date:  2022-04-01       Impact factor: 5.945

Review 3.  2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology.

Authors:  Soon Ho Yoon; Sang Min Lee; Chul Hwan Park; Jong Hyuk Lee; Hyungjin Kim; Kum Ju Chae; Kwang Nam Jin; Kyung Hee Lee; Jung Im Kim; Jung Hee Hong; Eui Jin Hwang; Heekyung Kim; Young Joo Suh; Samina Park; Young Sik Park; Dong Wan Kim; Miyoung Choi; Chang Min Park
Journal:  Korean J Radiol       Date:  2020-11-19       Impact factor: 3.500

4.  CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.

Authors:  Jung Han Woo; Tae Jung Kim; Tae Sung Kim; Joungho Han
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

5.  Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.

Authors:  Bo Da Nam; Soon Ho Yoon; Hyunsook Hong; Jung Hwa Hwang; Jin Mo Goo; Suyeon Park
Journal:  Korean J Radiol       Date:  2021-08-31       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.